Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
2.060
+0.190 (10.16%)
Nov 9, 2026, 1:57 PM EST - Market open
Foghorn Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Foghorn Therapeutics stock has a consensus rating of "Buy" and an average price target of $4.17. The average 1-year stock price forecast is 102.28% higher than the current stock price, while the lowest is $2.00 (-2.91%) and the highest is $5.00 (+142.72%).
Price Target: $4.17 (+102.28%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Foghorn Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Hold Downgrades $14 → $3 | Hold | Downgrades | $14 → $3 | +45.63% | Oct 13, 2026 |
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Maintains $12 → $5 | Buy | Maintains | $12 → $5 | +142.72% | Oct 2, 2026 |
| Wedbush | Wedbush | Hold Downgrades $10 → $2 | Hold | Downgrades | $10 → $2 | -2.91% | Oct 2, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $13 → $5 | Buy | Reiterates | $13 → $5 | +142.72% | Oct 2, 2026 |
| BTIG | BTIG | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Oct 1, 2026 |
Financial Forecast
Revenue This Year
28.71M
from 30.91M
Decreased by -7.10%
Revenue Next Year
6.43M
from 28.71M
Decreased by -77.59%
EPS This Year
-0.93
from -1.21
EPS Next Year
-1.03
from -0.93
EPS and Forward PE are based on non-GAAP adjusted numbers.